IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion

Erik Lubberts,1 Leo A.B. Joosten,1 Martine Chabaud,2 Liduine van den Bersselaar,1 Birgitte Oppers,1 Christina J.J. Coenen-de Roo,3 Carl D. Richards,4 Pierre Miossec,2 and Wim B. van den Berg1

1Rheumatology Research Laboratory, Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands
2Department of Immunology and Rheumatology, Hôpital Edouard Herriot, Lyon, France
3Department of Pharmacology, NV Organon, Oss, The Netherlands
4Department of Pathology, McMaster University, Hamilton, Ontario, Canada

Address correspondence to: Erik Lubberts, University Hospital Nijmegen, Department of Rheumatology, Rheumatology Research Laboratory, Post Office Box 9101, 6500 HB Nijmegen, The Netherlands.
Phone: 31-24-3616464; Fax: 31-24-3540403; E-mail: E.Lubberts@reuma.azn.nl.

Received for publication July 1, 1999, and accepted in revised form May 2, 2000.

Bone destruction is the most difficult target in the treatment of rheumatoid arthritis (RA). Here, we report that local overexpression of IL-4, introduced by a recombinant human type 5 adenovirus vector (Ad5E1mIL-4) prevents joint damage and bone erosion in the knees of mice with collagen arthritis (CIA). No difference was noted in the course of CIA in the injected knee joints between Ad5E1mIL-4 and the control vector, but radiographic analysis revealed impressive reduction of joint erosion and more compact bone structure in the Ad5E1mIL-4 group. Although severe inflammation persisted in treated mice, Ad5E1mIL-4 prevented bone erosion and diminished tartrate-resistant acid phosphatase (TRAP) activity, indicating that local IL-4 inhibits the formation of osteoclast-like cells. Messenger RNA levels of IL-17, IL-12, and cathepsin K in the synovial tissue were suppressed, as were IL-6 and IL-12 protein production. Osteoprotegerin ligand (OPGL) expression was markedly suppressed by local IL-4, but no loss of OPG expression was noted with Ad5E1mIL-4 treatment. Finally, in in vitro studies, bone samples of patients with arthritis revealed consistent suppression by IL-4 of type I collagen breakdown. IL-4 also enhanced synthesis of type I procollagen, suggesting that it promoted tissue repair. These findings may have significant implications for the prevention of bone erosion in arthritis.


Introduction

Bone destruction is the most difficult target in the treatment of rheumatoid arthritis (RA). Here, we report that local overexpression of IL-4, introduced by a recombinant human type 5 adenovirus vector (Ad5E1mIL-4) prevents joint damage and bone erosion in the knees of mice with collagen arthritis (CIA). No difference was noted in the course of CIA in the injected knee joints between Ad5E1mIL-4 and the control vector, but radiographic analysis revealed impressive reduction of joint erosion and more compact bone structure in the Ad5E1mIL-4 group. Although severe inflammation persisted in treated mice, Ad5E1mIL-4 prevented bone erosion and diminished tartrate-resistant acid phosphatase (TRAP) activity, indicating that local IL-4 inhibits the formation of osteoclast-like cells. Messenger RNA levels of IL-17, IL-12, and cathepsin K in the synovial tissue were suppressed, as were IL-6 and IL-12 protein production. Osteoprotegerin ligand (OPGL) expression was markedly suppressed by local IL-4, but no loss of OPG expression was noted with Ad5E1mIL-4 treatment. Finally, in in vitro studies, bone samples of patients with arthritis revealed consistent suppression by IL-4 of type I collagen breakdown. IL-4 also enhanced synthesis of type I procollagen, suggesting that it promoted tissue repair. These findings may have significant implications for the prevention of bone erosion in arthritis.

of osteoclastogenesis, as OPGL knockout mice did not show osteoclastic bone resorption (21).

In addition to the action of destructive mediators, the destructive process seems under the control of regulatory mediators such as IL-4 and IL-10. These modulatory cytokines have the potential to antagonize inflammatory and destructive mediators of the RA process effectively (22, 23). Marked protection of cartilage can be achieved with IL-4/IL-10 treatment (24, 25). Recently, we found impressive prevention of cartilage destruction by local IL-4 gene therapy, despite severe inflammation (26). Of great importance, IL-4 could not be detected in the synovium of patients with RA (27). This lack of IL-4 may contribute to the uneven balance between destructive and regulatory mediators in the synovium of the RA process. In vitro, IL-4 has been shown to be an inhibitor of bone resorption (28–31) and osteoclast-like cell formation (32, 33); however, its role in vivo has not been identified.

In the present study, we examined the impact of local IL-4 on bone erosion in the knee joint of mice with collagen-induced arthritis, using gene transfer with an IL-4–expressing adenoviral vector. In addition, we investigated the effects of IL-4 on the degradation and formation of collagen type I in bone samples from patients with arthritis. Collagen arthritis is an autoimmune model of RA, driven by the combination of cellular and humoral immunity against collagen type II (CII) and is characterized by rapid and severe erosions of cartilage and bone (34–36). Local IL-4 treatment impressively prevents joint damage and bone erosion, despite severe inflammation. The protective effect was associated with decreased formation of osteoclast-like cells and downregulation of IL-17, IL-6, IL-12, and OPGL in the synovium. In addition, mRNA levels of cathepsin K in synovial tissue was reduced in the IL-4 group. Interestingly, IL-4 prevented collagen type I breakdown, but enhanced the formation of type I procollagen in bone from patients with arthritis, suggesting promotion of tissue repair.

**Methods**

**Animals.** Male DBA-1/BOM mice were purchased from Bomholdgärd (Ry, Denmark). The mice were housed in filter-top cages. The mice were immunized ad libitum.

**Adenoviral vectors.** The recombinant replication-deficient adenovirus Ad5E1mIL-4 was generated by homologous recombination after cotransfecting 293 cells with PACCVMmIL-4 and a virus-rescuing vector pAdBHGI0 as described elsewhere (37). The empty recombinant replication-deficient adenovirus Ad5del70-3 was used as a control vector throughout the study. High titers of recombinant adenoviruses were amplified, purified, titered, and stored as described previously (38). Biologic activity of IL-4 produced by AdSE1mIL-4 was verified by blocking experiments with anti–IL-4 on AdE1mIL-4–induced inflammation and synovial cell mass.

**Intra-articular gene transfer with Ad5E1mIL-4.** Naïve mice were intra-articularly injected in the right knee joint with 10³, 10⁴, or 10⁵ pfu/μL of either Ad5E1mIL-4 or Ad5del70-3. At different time points, mice were bled and sacrificed by cervical dislocation. Patella with adjacent synovium was dissected in a standardized manner (25) from the right and the contralateral knee. The levels of IL-4 in sera and washouts of joint tissue were measured by ELISA as described later here.

**Induction of collagen-induced arthritis.** Bovine type II collagen was prepared as described (24) and diluted in 0.05 M acetic acid to a concentration of 2 mg/mL and was emulsified in equal volumes of CFA (2 mg/mL of Mycobacterium tuberculosis; strain H37Ra; Difco Laboratories, Detroit, Michigan, USA). The mice were immunized intradermally at the base of the tail with 100 μL of emulsion (100 μg of collagen). On day 21, mice were given an intraperitoneal booster injection of 100 μg of type II collagen dissolved in PBS, and normally arthritis onset will then occur around days 25–28.

**Study protocol.** The collagen arthritis model (CIA) was induced in male DBA-1 mice as already described here. Just before expected onset of CIA, mice were scored visually for the appearance of arthritis. Mice without macroscopic signs of arthritis in the paws were selected. Mice were anesthetized with ether, and a small aperture in the skin of the knee was prepared for the intra-articular injection procedure. When absence of arthritis was confirmed in the knee joint, intra-articular injections were performed with 10³ pfu/μL of either an IL-4–expressing (Ad5E1mIL-4) or an empty control (Ad5del70-3) recombinant human type 5 adenovirus vector or with saline (26). At days 1, 3, 5, and 7 after the intra-articular injection of the viral vector, mice were sacrificed by cervical dislocation, and the skin of the knee joint was removed. The appearance of arthritis in the injected joints was assessed and severity score was recorded as described previously (24). Thereafter, knee joints were isolated and processed for light microscopy.

**Assessment of arthritis.** Mice were considered to have arthritis when significant changes in redness and/or swelling were noted in the digits or in other parts of the paws. Knee joint inflammation was scored visually after skin dissection, using the following scale: 0, non-inflamed; 1, mild inflammation; 1.5, marked inflammation; 2, severe inflammation. Scoring was done by two independent observers, without knowledge of the experimental groups.

**Assessment of IL-4, IL-6, and IL-12 protein in 1-hour patella washouts.** To determine the levels of IL-4, IL-6, and IL-12 in patella washouts, patellae were isolated in a standardized manner from knee joints as described previously (25). Patella were incubated in RPMI 1640 medium (GIBCO BRL, Breda, The Netherlands) with 0.1% BSA, gentamicin (50 μg/mL), and l-glutamine (2
mM) (200 µL/patella) for 1 hour at room temperature. After supernatant was harvested the IL-4, IL-6, and IL-12 levels were measured by ELISA (25, 26). Anti-murine IL-4 antibodies (Ab’s) were purchased from PharMin- gen (San Diego, California, USA; capture Ab: rat anti-mouse IL-4 mAb [clone: BVD4-1D11]; detection Ab: rat anti-mouse IL-4 mAb biotin labeled [clone: BVD6-24G2]). The detection range of the IL-4 ELISA is 1.280–1.2 pg/mL. The sensitivity of the IL-4 ELISA is 5 pg/mL. No cross-reactivity was found with the cytokines IL-1, IL-6, or IL-10. Anti-murine IL-6 Ab’s were from Biosource International (Camarillo, California, USA; capture Ab: rat anti-mouse IL-6 mAb [clone: MP5-20F3]; detection Ab: rat anti-mouse IL-6 mAb biotin labeled [clone MP5-32C2]). The detection range of the IL-6 ELISA is 2,560–40 pg/mL, with a sensitivity of 78 pg/mL. No cross-reactivity was found with the cytokines IL-1β, IL-4, and IL-10. Anti-murine IL-12 Ab’s were obtained from Genzyme (Cambridge, Massachusetts, USA; capture Ab: monoclonal rat anti-mouse IL-12 [clone C15.6]; detection Ab: monoclonal rat anti-mouse IL-12 biotin labeled [clone C17.8]). The detection range of the IL-12 ELISA is 1,280–1.2 pg/mL, with a sensitivity of 10 pg/mL. No cross-reactivity was found with IL-4, IL-6, TNF-α, and IL-1.

Briefly, ELISA plates (Maxisorb; Nunc, Copenhagen, Denmark) were coated with the capture Ab (3 µg/mL) by overnight incubation at 4°C in 0.1 M carbonate buffer (pH 9.6). Nonspecific binding sites were blocked by 1-hour incubation at 37°C with 1% BSA in PBS/Tween-20. The supernatants were tested by 3-hour incubation at 37°C. The plates were then incubated at 37°C with the biotin-labeled second Ab (0.25 µg/mL) diluted in PBS/0.5% BSA (pH 7.5), followed by a 30-minute incubation at 37°C with streptavidin conjugated to poly-horseradish peroxidase (0.25 µg/mL) (source: Streptomyces avidinii; Central Laboratory of Blood Transfusion, Amsterdam, The Netherlands) diluted in 1% casein colloid/PBS buffer (pH 7.5) (Central Laboratory of Blood Transfusion). Bound complexes were detected by reaction with 0.08% orthophenylenediamine (OPD) diluted in 50 mM phosphate buffer (pH 6.0) and 0.03% H₂O₂. Absorbance was measured at 492 nm using an ELISA plate reader (Titertek Multiscan MCC/340; Labsystems, Helsinki, Finland). The cytokine concentration in the samples was calculated as picograms per milliliter using recombinant mouse IL-4 (a kind gift of S. Smith [Schering-Plough, Kenilworth, New Jersey, USA]), IL-6 (Biosource International) and IL-12 (kindly provided by S. Wolf, Genetic Institute Inc., Cambridge, Massachusetts, USA) as a standard.

Isolation of RNA. Mice were sacrificed by cervical dislocation, and the patella and adjacent synovium were immediately dissected (39). Synovium biopsy tissue was taken from six patella specimens. Two biopsy spec- imens with a diameter of 3 mm were punched out, using a biopsy punch (Stifle, Wachtersbach, Germany): one from the lateral side and one from the medial side. Three lateral and three medial biopsy samples were pooled to yield two samples per group. The synovium samples were immediately frozen in liquid nitrogen. Synovium biopsy samples were ground to powder using a microdismembrator II (Braun Inc., Melsungen, Germany). Total RNA was extracted in 1 mL of Trizol reagent (GIBCO BRL), a monophasic solution of phenol and guanidine isothiocyanate, which is an improved single-step RNA isolation method based on the method described by Chomczynski and Sacchi (40).

PCR amplification. One microgram of synovial RNA was used for RT-PCR. Messenger RNA was reverse transcribed to complementary DNA (cDNA) using oligo-DT primers, and one twentieth of the cDNA was used in one PCR amplification. PCR was performed at a final concentration of 200 µM dNTPs, 0.1 µM of each primer, and 1 unit of Tag polymerase (GIBCO BRL) in standard PCR buffer (20 mM Tris-HCl [pH 8.4] and 50 mM KCl) (GIBCO BRL). The mixture was overlaid with mineral oil and amplified in a thermocycler (Omni- gene, Hybaid, United Kingdom). Message for GAPDH was amplified using the primers described elsewhere (24). Primers for cathepsin K, IL-17, IL-12, OPGL and osteoprotegerin (OPG) were designed using Oligo 4.0 and Primer Software (Molecular Biology Insights Inc., Cascade, Colorado, USA). For every mediator that is tested in the PCR reaction, GAPDH expression was also measured in the same reaction mix. Samples (5 µL) were taken from the reaction tubes after a certain number of cycles. PCR products were separated on 1.6% agarose and stained with ethidium bromide. The expression for GAPDH is normalized between the control vector group and the IL-4 group before differences in mRNA expression for a particular mediator were determined.

Radiology. At the end of the experiment, knee joints were isolated and used for x-ray analysis as a marker for joint destruction. X-ray films were carefully examined using a stereo microscope, and joint destruction was scored on a scale of 0–5, ranging from no damage to complete destruction of the joint.

Tartrate-resistant acid phosphatase staining. At the end of the experiment, whole knee joints were fixed for 2 days in 10% formalin, followed by decalcification in 10% EDTA (Titireplex III; Merck, Darmstadt, Germany) in 1 mM Tris-HCl (pH 7.4) for up to 2 weeks at 4°C (10). Decalcified specimens were processed for paraffin embedding (41). Staining of tissue sections (7 µm) for tartrate-resistant acid phosphatase (TRAP) was performed by a leukocyte acid phosphatase kit, a cell-staining kit for the detection of tartrate resistant acid phosphatase from Sigma Chemical Co. (St. Louis, Missouri, USA).

Histology. Whole knee joints were removed and fixed for 4 days in 10% formalin. After decalcification in 5% formic acid, the specimens were processed for paraffin embedding (41). Tissue sections (7 µm) were stained with hematoxylin and eosin (H&E) or Safranin O. Histopathological changes were scored using the fol-
ollowing parameters. Infiltration of cells was scored on a scale of 0–3, depending on the amount of inflammatory cells in the synovial cavity (exudate) and synovial tissue (infiltrate). A characteristic parameter in CIA is the progressive loss of bone. This destruction was graded on a scale of 0–3, ranging from no damage to complete loss of the bone structure.

Histopathological changes in the knee joints were scored in the patella and femur/tibia regions on five semiserial sections of the joint, spaced 70 μm apart. Immunohistochemistry was quantified using an automated image analysis system (Leica Q500/N; Leica Imaging Systems Ltd., Cambridge, United Kingdom). Microscopic images were recorded by a CDD video camera (Victor Company of Japan Ltd., Tokyo, Japan) and processed by a personal computer. Optical density was measured in the cartilage or synovium. For cartilage, the whole area of noncalcified cartilage was scanned, and staining was expressed per unit of tissue (μm²). For synovium, a defined area along the cortical bone was scanned, using a standardized template. Five sections per joint were scanned. Staining values were corrected for background staining, as measured in the control vector group. Scoring was performed by two observers without knowledge of the experimental group, as described earlier (24).

**Immunohistochemistry of OPGL.** Whole knee joints were fixed, decalcified and paraffin embedded as already described here. Tissue sections (7 μm) were treated with 1% H₂O₂ for 10 minutes at room temperature. Sections were incubated for 1 hour with the primary Ab RANKL (goat polyclonal Ab raised against a peptide mapping at the NH₂-terminus of RANKL (RANK ligand) of mouse origin (N-19; Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) or a control goat IgG Ab (Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA). After rinsing, sections were blocked with 4% normal mouse serum for 20 minutes at room temperature. Thereafter, sections were incubated for 30 minutes with biotinylated mouse anti-goat IgG (Jackson ImmunoResearch Laboratories) and detected using biotin-streptavidin/peroxidase staining (Elite kit; Vector Laboratories, Burlingame, California, USA). Development of the peroxidase staining was done with 3',3'-diaminobenzidine (Sigma Chemical Co.). Counterstaining was done with Mayer’s hematoxylin.

**Immunohistochemical staining of type II collagen neoepitopes.** Whole knee joints were fixed for 2 days in 10% formalin, followed by decalcification in 10% EDTA (Titriplex III), 7.5% polyvinylpyrrolidone (PVP; M, 29,000; Serva, Amsterdam, The Netherlands) in 0.1M phosphate buffer (pH 7.4) for 2 weeks at 4°C. After extensive rinsing with 7.5% PVP in 0.1M phosphate buffer, tissue blocks were rapidly frozen in liquid nitrogen and stored at −70°C. Whole knee joint sections (7 μm) were cut at 22°C on a cryostat and mounted on glass microscope slides precoated with 3-aminopropyltriethoxysilan (Sigma Chemical Co.). Sections were dried for 1 hour and stored at −70°C until further use. After thawing, the sections were fixed in freshly prepared 4% formaldehyde (5 minutes) and washed extensively in 0.1 M PBS (pH 7.4) for 15 minutes. Sections were incubated with 1% hyaluronidase (type I-s; Sigma Chemical Co.) for 30 minutes at 37°C, to remove proteoglycans. After treatment with 1% H₂O₂ for 30 minutes, nonspecific staining was blocked by incubation with 10% normal goat serum with 1% BSA. Sections were incubated overnight with the primary rabbit Ab Col2-3/4Cshort (kindly provided by A.R. Poole [McGill University, Montreal, Canada]) directed against the COOH-terminal neoepitope generated by cleavage of native human type II collagen by collagenases, which has been described and characterized previously (42). The Col2-3/4Cshort antiserum detects the COOH-terminal neoepitope that can be generated by

![Figure 1](http://www.jci.org)

**Figure 1.** Adenoviral vector–mediated IL-4 expression in the mouse knee joint. (a) 1.10⁷ pfu of Ad5E1mIL-4 was given intra-articularly to naive C57bl/6 mice and patella with adjacent synovium was taken in a standardized manner on days 1, 2, 4, 7, and 14 to measure IL-4 in the washouts of joint tissue by ELISA. The control vector of the same dose and the washouts from the contralateral knee both gave rise to undetectable levels of IL-4 (not graphed). Results are expressed as mean ± SD of four mice per time point. (b) Various doses of AdE1mIL-4 were given intra-articularly to naive C57bl/6 mice, and IL-4 was measured in washouts of joint tissue at day 7 by ELISA. Results are expressed as mean ± SD of four mice per dose. The detection limit of the mL-4 ELISA is 5 pg/mL.
matrix metalloprotease-1 (MMP-1), MMP-8, MMP-13, and probably also by MMP-2 (43). After extensive rinsing, sections were incubated with biotinylated goat anti-rabbit IgG and detected using biotin-streptavidin/peroxidase staining (Elite kit). Development of the peroxidase staining was done with 3',3'diaminobenzidine (Sigma Chemical Co.). Counterstaining was done with Mayer’s hematoxylin.

Preparation of bone fragments. Rheumatoid bone samples were obtained from patients with osteoarthritis (OA) and RA, according to the revised criteria of the American College of Rheumatology (44), who were undergoing knee or wrist synovectomy, or joint replacement. Bone fragments were prepared as described previously (30). Samples were cut into small pieces of approximately 2 mm³ and incubated in triplicate in complete medium consisting of MEM medium (GIBCO BRL), 2 mM L-glutamin, 100 U/mL penicillin, 50 mg/mL gentamycin, 20 mM HEPES buffer, and 10% FCS. Cultures were performed at 37°C in a 5% CO2/95% humidified air. Bone fragments were cultured in 24-well plates (Falcon, Oxnard, CA) in a final volume of 2 mL. The cytokines to be tested were added at the beginning of the culture.

Measurement of collagen degradation. Type I collagen C-telopeptide breakdown products (CTX) were measured in synovium piece culture supernatants by a two-site ELISA (Serum Crosslaps One-Step, Osteometer Biotech, Ballerup, Denmark) using two mAb’s raised against a synthetic peptide with an amino acid sequence specific for a part of the C-telopeptide of α1-chain of type I collagen (45). Intra- and interassay CVs are lower than 5% and 8%, respectively, and the sensitivity is 154 pmol/L.

Determination of type I collagen production. The production of type I collagen was estimated in 48-hour culture media by measuring the concentration of the C-propeptide of type I collagen (PICP) using a two-site ELISA that uses an mAb and a polyclonal Ab raised against human PICP purified from skin fibroblast cultures (Procollagen-C, Metra Biosystem Inc., Palo Alto, California, USA) (46, 47). The sensitivity of the assay is 1 ng/mL, and the intra- and interassay CV were below 7%.

Statistical analysis. Means ± SD of the various groups were determined and potential differences between experimental groups were tested using the Mann-Whitney rank sum test, unless stated otherwise.

Results

Intra-articular Ad5E1mIL-4 gene transfer in the mouse knee joint. Naive C57bl/6 mice were intra-articularly injected in the right knee joint with 1.10⁷ pfu of either Ad5E1mIL-4 or Ad5del70-3 before onset of CIA was noted. At days 1, 3, 5, and 7 after intra-articular injection of the viral vector, mice were sacrificed by cervical dislocation, and the skin of the knee joint was removed. The appearance of arthritis in the injected joints was visually scored for severity (arthritis score). Results are the mean ± SD of two separate experiments with a total of at least 22 mice per group. Ad control, Ad5del70-3.

Analysis of the inflammatory aspects of local IL-4 overexpression in the knee joint of mice with collagen-induced arthritis. Knee joints were taken for histology. Synovial infiltrate and exudate were scored on a scale of 0–3. Results are the mean ± SD of four separate experiments with at least eight mice per group per experiment. For details, see Figure 2.
IL-4 levels in time was not due to autoinduction of IL-4. The adenoviral vector–mediated IL-4 expression in the mouse knee joint was vector dose related (Figure 1b). No detectable levels of IL-4 were found in washouts from the contralateral knee or the Ad5del70-3 control vector injected knee or in sera from Ad5E1mIL-4–injected animals (data not shown).

Intra-articular Ad5E1mIL-4 gene transfer in the knee joint of CII-immunized mice. DBA-1 mice were immunized with CII, and shortly before expected onset of collagen arthritis, a single injection of $1 \times 10^7$ pfu of Ad5E1mIL-4 or control vector was given in the right knee joint. At days 7 and 14 after the intra-articular injection of Ad5E1mIL-4, relatively high IL-4 levels ($333 \pm 105$ and $416 \pm 230$ pg/mL, respectively) were measured in washouts of joint tissue of the IL-4 group. No detectable IL-4 was noted in washouts of the knee joints injected with the control vector (Ad5del70-3). No difference was noted in the course of the collagen arthritis in the injected knee joints between the IL-4 group and the control vector group (Figure 2). In line with our previous study (26), at day 7, a 100% arthritis incidence was noted in the right knee joint of the IL-4 group with a severity score of $2.0 \pm 0.2$ compared with $90\%$ incidence in the control vector group with an arthritis score of $1.8 \pm 0.6$ (Figure 3). No obvious differences in severity were found in the infiltrate and exude between the Ad5E1mIL-4 group and the Ad5del70-3 control group (Figure 3).

IL-4 prevents collagen breakdown during collagen arthritis. Collagen breakdown leads to irreversible joint damage. We investigated the impact of local IL-4 application on collagen breakdown during collagen arthritis. Histological knee joint sections were stained with Ab's recognizing type II collagen breakdown neoepitopes. We found less collagen type II breakdown neoepitope expression in the IL-4 group compared with the control group ($72 \pm 16\%$ [SD] suppression; mean of 10 samples) (Figure 4), which is in line with our earlier findings that IL-4 prevents cartilage erosion.

Local IL-4 overexpression prevents localized bone erosion during collagen arthritis. Whole knee joints were radiologically scored for the degree of joint destruction. Seven and 14 days after the viral injection, x-ray analysis showed marked joint destruction in the control vector group (Figures 5 and 6, b and d). Interestingly, local IL-4 treatment strongly reduced the degree of joint destruction (75%) ($P < 0.001$) (Figure 5). At days 7 and 14 after the viral injection, marked prevention of joint damage was still noted in the IL-4 group compared with the control vector group (Figure 6, c and e). In addition, mice were ranked for individual scores of arthritis treatment.

**Table 1**

<table>
<thead>
<tr>
<th>Joint destruction</th>
<th>Ad5del70-3</th>
<th>Ad5E1mIL-4</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Mild</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>Marked</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Severe</td>
<td>4</td>
<td>0</td>
</tr>
</tbody>
</table>

*See Figure 4 for more detail on the experimental protocol. *Arthritic mice were classified according to their degree of joint destruction, as scored radiologically on whole knee joints. Whole knee joints were scored using a scale of no changes (none), minor destruction, one spot per area (mild), marked changes in more areas (marked), and severe erosions affecting the joint (severe). $\chi^2$ test showed significance ($P < 0.001$) between Ad5E1mIL-4 and Ad5del70-3 treatment comparing none/mild and marked/severe groups. $^c$Number of mice.

**Figure 5**

X-ray analysis of joint damage in CIA after one intra-articular injection of Ad5E1mIL-4. Immunized DBA-1 mice were injected intra-articularly in the right knee with $1 \times 10^7$ pfu of Ad5E1mIL-4 or Ad5del70-3 before onset of CIA was noted. Seven days later, mice were sacrificed by cervical dislocation, and the knee joints were taken for x-ray analysis. Joint damage was scored on a scale of 0–5. Results are the mean ± SD with 12 mice per group. $^dP < 0.001$ versus control group, by Mann-Whitney rank sum test.

**Figure 4**

Effects of local IL-4 on collagen breakdown. (a) Arthritic knee joint of a mouse 7 days after intra-articular injection of $1 \times 10^7$ pfu of Ad5del70-3 showing staining for type II collagen breakdown epitope, detected with mAb Col2-3/4Cshort. (b) Knee joint of a mouse 7 days after intra-articular injection of $1 \times 10^7$ pfu of Ad5E1mIL-4. Note the decreased staining of collagen type II breakdown epitope. a and b, $\times \text{250}$. 

**IL-4** prevents collagen breakdown during collagen arthritis. Collagen breakdown leads to irreversible joint damage. We investigated the impact of local IL-4 application on collagen breakdown during collagen arthritis. Histological knee joint sections were stained with Ab’s recognizing type II collagen breakdown neoepitopes. We found less collagen type II breakdown neoepitope expression in the IL-4 group compared with the control group ($72 \pm 16\%$ [SD] suppression; mean of 10 samples) (Figure 4), which is in line with our earlier findings that IL-4 prevents cartilage erosion.

**Local IL-4 overexpression** prevents localized bone erosion during collagen arthritis. Whole knee joints were radiologically scored for the degree of joint destruction. Seven and 14 days after the viral injection, x-ray analysis showed marked joint destruction in the control vector group (Figures 5 and 6, b and d). Interestingly, local IL-4 treatment strongly reduced the degree of joint destruction (75%) ($P < 0.001$) (Figure 5). At days 7 and 14 after the viral injection, marked prevention of joint damage was still noted in the IL-4 group compared with the control vector group (Figure 6, c and e). In addition, mice were ranked for individual scores of arthritis treatment.
joint destruction in four subclasses (Table 1). Whereas the majority of mice of the control group were ranked as having severe destruction, none of the mice of the IL-4 group was in this category. All mice of the IL-4 group were ranked as having no or mild destruction.

A characteristic histological parameter in collagen arthritis is the progressive loss of bone at the joint margins. Subchondral and cortical bone destruction was scored on semiserial knee joint sections in the patella and femur/tibia region. Hyperplastic synovial tissue, consisting of synoviocytes extends over the cortical bone surface of the patella and femur/tibia in the arthritic control group and the IL-4–treated group (Figure 7a). Profound bone erosions were found in the control, arthritic group (Figures 7b, and 8, a–d). Destruction of subchondral bone in the patella and femur region was noted (Figure 7c). Lateral and medial sites of the cortical bone of the patella and several parts of the femur/tibia were completely eroded (Figure 7d). Synoviocytes were noted in the erosion front. Inflammatory tissue seems to invade into the bone at sites of bone erosion. Of high interest, despite the lack of difference in hyperplasia of synovial tissue that extends over the bone surface (Figure 7a), the degree of bone erosion was highly reduced in the IL-4–treated group ($P < 0.001$) (Figures 7 and 8, e–h). Mean values of two separate experiments revealed 70% and 68% reduction for this parameter in the subchondral bone of the patella and femur/tibia, respectively, and 58% and 62% reduction in the cortical bone of the patella and femur/tibia, respectively, in the IL-4 group compared with its respective adenoviral vector group.

**Effects of IL-4 on osteoclast-like cells.** Osteoclasts are potent bone resorbing cells and play an important role in joint destruction. TRAP activity is a characteristic phenotypic marker of osteoclasts and osteoclast precursors and is expressed in osteoclast-like cells in murine collagen-induced arthritis (10). To demonstrate further the protective effect of local IL-4, TRAP staining was performed on paraffin-embedded knee joint sections. TRAP-positive mononuclear cells were found in the erosive front in the control vector group.
Local IL-4 overexpression in the knee joint of CII-immunized mice highly decreased the number of TRAP-positive mononuclear cells, indicating that IL-4 inhibits the formation of osteoclast-like cells (Figure 9, e–h). The mechanism(s) involved in the formation and activation of osteoclasts in RA is still unknown. However, locally produced cytokines in the synovium, such as IL-1, IL-6, and TNF-α, could provide signals for osteoclast differentiation and bone resorption (14–17). Local IL-4 gene therapy reduces the IL-1β protein level (76%) found in the washouts of synovial tissue (26). No significant levels of free TNF-α was found in tissue washouts of either the IL-4–treated group or the control vector group (data not shown). IL-6 protein was much lower (56%) in the synovium washouts of the IL-4–treated group compared with the control vector group (Figure 10). Local IL-4 suppresses IL-17 and OPGL expression in the synovium. Many of the cytokines known to stimulate bone resorption act through the upregulation of a novel and essential factor for osteoclastogenesis, OPGL (21). OPGL is produced by different cell types, including activated T cells (49). IL-17 is a T-cell–derived cytokine that was found in the synovium of a patient with RA and is a potent stimulator of osteoclastogenesis (19, 20). To get a better impression of potential changes in mediators involved in T-cell–driven activation, we analyzed IL-17 and IL-12 mRNA levels, using RT-PCR. Both cytokines were strongly reduced in the IL-4–treated mice and marked reduction of IL-12 protein levels (74%) was found (Table 2; Figure 10b).

OPGL expression was found in the synovium and at places where bone erosion takes place using RT-PCR and immunohistochemistry (Table 2; Figure 11). Intriguingly, OPGL expression was greatly reduced in the synovium by local IL-4 (Table 2; Figure 11c: 57 ± 12% [SD] suppression, mean of 10 samples). No difference in OPG mRNA expression
was noted between the IL-4 group and the control group (Table 2).

**Ad5E1mIL-4 suppresses cysteine proteinase cathepsin K mRNA expression in synovial tissue.** Cysteine proteinase cathepsin K probably is involved in osteoclast-mediated bone resorption (13, 50). Upregulation of cathepsin K mRNA expression in RA synovium compared with normal synovium has been reported (50). Cathepsin K was not only expressed by osteoclast but also by synovial fibroblast, suggesting that cathepsin K contributes to bone destruction mediated by RA synovial cells (50). We investigated the effects of local IL-4 overexpression on the cathepsin K expression in the synovial tissue. RT-PCR measurements revealed a strongly reduced level of cathepsin K in the synovial tissue by Ad5E1mIL-4 (Table 2).

**IL-4 prevents collagen type I degradation in bone from patients with RA and those with OA.** The major collagen type found in bone is type I collagen. The increased rate of bone destruction is reflected by a COOH-terminal peptide released during the degradation of type I collagen. The effects of IL-4 on type I collagen CTX was tested in bone samples from five patients with RA and four with OA. CTX was found in the supernatants of these patients. Incubation with IL-4 for 7 days markedly suppressed CTX in the supernatant of all patients (mean: 70% for RA and 65% for OA), indicating that IL-4 strongly prevented collagen type I degradation (Table 3). In addition, we analyzed the effects of IL-4 on the synthesis of type I procollagen. It was found in all samples that formation was enhanced (mean: 77% for RA and 85% for OA), suggesting promotion of tissue repair (Table 3).

**Discussion**
We clearly demonstrated marked protection against joint destruction by local IL-4 overexpression in the inflamed joint. Radiological and histological analysis revealed pronounced protection against cartilage and
bone erosion, despite full-blown arthritis. This protective effect of local IL-4 was associated with decreased formation of osteoclast-like cells and downregulation of IL-17, IL-6, IL-12, OPGL, and cathepsin K expression in the synovium. Furthermore, IL-4 inhibits the breakdown of type I collagen in bone samples from patients with arthritis. Interestingly, promotion of tissue repair by IL-4 was suggested through upregulation of type I procollagen in these cultures.

Lack of regulatory mediators such as IL-4 may contribute to the uneven balance of destructive and modulatory mediators in the synovium of the RA process. Understanding the regulation of the destructive process, the cytokines and cells that are involved may provide better therapeutic approaches in patients with RA. It is now generally accepted that TNF-α and IL-1 are key mediators in RA, and these proinflammatory cytokines play a critical role in the CIA (51).

Studies in animal models identified the pivotal role of IL-1 in cartilage matrix degradation, whereas TNF-α plays a major role in the inflammatory process (51–56). Enhanced IL-1β protein levels were found in the arthritic synovial tissue (26), whereas, TNF-α protein levels were low in both the control vector and IL-4–expressing vector group, suggesting that IL-1 is enhancing osteoclast formation in CIA. Of high interest, local IL-4 treatment strongly reduced local IL-1 (26) in the arthritic synovium, indicating that IL-4 is an important regulator of this destructive mediator.

Protection of bone erosion was associated with decreased formation of osteoclast-like cells in the IL-4–treated mice. Locally produced cytokines in the synovium could provide signals for osteoclast differentiation and bone resorption (14–17). In addition to IL-1, IL-6 has been shown to be a powerful stimulator of osteoclast bone resorption. It is produced by the inflamed synovium and found in large amounts in RA synovial fluid (57, 58). It can induce osteoclast development and was shown to be directly involved in bone resorption in an in vivo model of osteoporosis, related to estrogen loss (59). Anti–IL-6 is inhibitory to osteoclast-like cell formation (10). In the present study, we found marked reduction of IL-6 in the arthritic synovium tissue after local IL-4 treatment, indicating that the mechanism of decreasing the number of osteoclast-like cells by local IL-4 treatment may, at least in part, be mediated by suppressing this important osteoclast stimulator. It is not yet clear whether IL-4 directly reduced IL-6 production or whether this is a result of marked suppression of IL-1 (26). Osteoclasts differentiate from hematopoietic monocyte/macrophage precursors (4, 21). It has been demonstrated that osteoclast formation can occur in the absence of any bone or bone marrow–derived cells (60). Furthermore, it has been shown that synovial macrophages are capable of differentiating into osteoclasts in the presence of rheumatoid synovial fibroblasts (60), revealing that rheumatoid synovial cells contain both osteoclast progenitors and stromal cells supporting their differentiation (60). OPGL may play an important role in this differentiation pathway, as OPGL is considered a novel key regulator of osteoclastogenesis (21). Many of the cytokines known to stimulate bone resorption act through the upregulation of this novel and essential factor. The synovial lining is normally a thin layer, one to two

---

**Table 2**  
Synovial mRNA levels after AdSE1mIL-4 treatment

<table>
<thead>
<tr>
<th></th>
<th>PCR cycles</th>
<th>Δ₀</th>
</tr>
</thead>
<tbody>
<tr>
<td>AdSd70-3</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>AdSE1mIL-4</td>
<td>&gt; 42</td>
<td>-8</td>
</tr>
<tr>
<td>AdSd70-3</td>
<td>30</td>
<td>36</td>
</tr>
<tr>
<td>AdSE1mIL-4</td>
<td>30</td>
<td>34</td>
</tr>
<tr>
<td>OPGL</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>OPG</td>
<td>30</td>
<td>0</td>
</tr>
<tr>
<td>Cathepsin K</td>
<td>30</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>-5</td>
</tr>
</tbody>
</table>

*Synovial mRNA levels were determined by RT-PCR technology, 7 days after the viral injection. Total RNA from six synovium biopsies of three mice were pooled, yielding two samples per group, as described in Methods. Values are the mean of two experiments with 12 mice per group. The PCR measurements of a particular mediator were routinely repeated three times. Samples (5 μL) were taken at two-cycle intervals, with a total of six samples applied to the gel. The variations in the two repeated experiments never exceeded more than two cycles. **Number of PCR cycles in which gene product of interest was first detectable. △**Messenger RNA expression was determined 7 days after the viral injection. △ refers to the difference between the respective AdSd70-3– and AdSE1mIL-4–treated conditions.
cells in thickness, which consist of type A and B cells, showing macrophages and fibroblast-like properties. During (chronic) joint inflammation, considerable thickening of the lining is a characteristic event, and the subsynovial tissue becomes infiltrated by numerous macrophages and lymphocytes. Therefore, osteoclasts differentiated from monocyte/macrophage precursors in the synovial membrane are probably involved in bone destruction in arthritis. Interestingly, we found OPGL expression in the synovium and at sites where bone erosion takes place in the arthritic control group. Furthermore, we found osteoclast-like cells in the erosive front in the knee joint of the arthritic control mice showing severe joint destruction, which is compatible with an earlier study demonstrating direct participation of osteoclast-like cells in the joint destruction of CIA (10). Moreover, at bone erosion sites, the receptor of OPGL, RANK was expressed in areas were OPGL expression was found (E. Lubberts et al., manuscript in preparation). Remarkably, local IL-4 treatment suppressed OPGL expression and highly reduced numbers of osteoclast-like cells, suggesting that local IL-4 overexpression interferes in the differentiation pathway of macrophage precursors to osteoclasts.

We found reduced numbers of osteoclast-like cells after local IL-4 treatment, whereas the amount of inflammatory cells in the synovial tissue was not reduced. A similar situation has been described in osteomyelitis, where reduced osteoclast activity was observed in bone adjacent to infection, without a notable decrease in the inflammatory mass (61). This suggests that the inflammatory cells can be there, but do not necessarily display a destructive phenotype. It was shown that the T-cell–derived cytokine IL-17, which is expressed in the synovium of patients with RA (19, 20), is a potent stimulator of osteoclastogenesis (19). To get a better impression of potential changes in mediators involved in T-cell–driven activation, we analyzed IL-12 and IL-17 levels. Both cytokines were strongly reduced in the IL-4–treated mice. Activated, but not resting, T cells can directly trigger osteoclastogenesis through OPGL (49), and, as already discussed, also OPGL mRNA expression was greatly reduced. Interestingly, no difference was found in OPG expression between the control group and the IL-4 group, suggesting that IL-4 suppresses the OPGL/OPG balance. These data indicate that T-cell–driven OPGL production is a pivotal element in bone erosion in collagen arthritis and that IL-4 inhibits this process either directly, or through down-regulation of cytokines involved in T-cell maturation and mediator production. Investigation into further characterization of the IL-12, IL-17, and OPGL interplay is currently under way.

Cysteine proteinase cathepsin K expression is highly tissue specific and is predominantly expressed in osteoclasts (62, 63) and fibroblasts, but hardly in macrophages (50). Cathepsin K has been suggested to be a key enzyme in diseases associated with excessive loss of bone (50). In the present study, we found marked reduction of mRNA expression of cathepsin K in synovial tissue by local IL-4, which is in line with reduced numbers of osteoclast-like cells. In addition, it implies that IL-4 may have a direct effect on the cathepsin K production in fibroblasts.

In most metabolic bone diseases, both bone formation and bone resorption are altered. To analyze these elements in bone samples of patients with arthritis,
we have taken the same biochemical assays as are used routinely in bone metabolic studies. This includes the measurement of PICP as a marker of procollagen synthesis by osteoblasts and CTX, a COOH-terminal peptide, as a marker of type I collagen degradation (64–66). Earlier studies already indicated that high serum and urinary levels of CTX reflect increased bone destruction in patients with RA, and a positive correlation with x-ray destruction was demonstrated (67). In the present study, we show that IL-4 can suppress CTX release in cultures of bone explants of patients with arthritis, but also enhanced the formation of type I procollagen. As such, IL-4 exerts a dual positive effect. This adds clinical relevance to the convincing protective effect noted with IL-4 in the collagen arthritis model.

Cartilage damage is usually linked to bone erosion, and MMPs are crucial in late, irreversible cartilage damage. In the present study, we confirmed the cartilage protective effect of local IL-4 (26) and found less collagen type II breakdown neoepitope expression, which can be generated by MMP-1, -8, -13, and probably also by MMP-2 (43). This suggests that IL-4 reduces collagenase activity, either directly or through reduction of stromelysin-1, which is essential in collagenase activation. Further characterization of the IL-4 effect on MMP activity is warranted.

Previous studies from our group have revealed the potential uncoupling of inflammation and joint destruction. TGF-β showed enhanced fibrosis but ameliorated cartilage damage (68). In addition, selective elimination of synovial lining cells with toxic liposomes can prevent the expression of joint inflammation; however, this treatment is not necessarily protective against cartilage damage (68). Furthermore, OPG treatment in adjuvant-induced arthritis completely abolished the loss of mineral bone density however, had no effect on the severity of inflammation (49). Another important demonstration showing protection of the skeleton from damage when inflammation is essentially unaffected was reported by Bresnihan et al. (69). In this human clinical study with IL-1 receptor antagonist, beneficial effect on the rate of joint erosion was shown, although the inflammation was not significantly arrested. The present study clearly shows uncoupling of inflammation and surface erosion of bone and cartilage. All of this underscores the concept that the balance of destructive and protective mediators determines the relative erosive nature of a given arthritis, rather than the bulk of the inflammatory mass.

In conclusion, this is the first report demonstrating clear bone protective effects of local IL-4 gene therapy in experimental arthritis, despite severe inflammation. Furthermore, IL-4 prevented collagen type I degradation in bone samples of patients with arthritis, and interestingly, it stimulated the formation of type I procollagen. Because the control of bone destruction is the most difficult target in the treatment of patients with arthritis, our data have significant implications for the prevention of bone erosion in arthritis.

Acknowledgments
We acknowledge The Central Animal Laboratory, Faculty of Medicine, University of Nijmegen for animal care. We thank A.R. Poole for providing us with Col2-3/4Cshort Ab, and M. Helsen and E. Vitters for technical assistance. This work was supported by grants from The Dutch League against Rheumatism (grant 742) and from the European Union (Biomed-2 Program BMH4-CT96-1698), and partially by the Hamilton Health Sciences Corp., and St. Joseph’s Hospital, Hamilton, Ontario, Canada.


Table 3
IL-4 prevents collagen type I breakdown but enhances procollagen type I formation in bone from patients with arthritis (49).

<table>
<thead>
<tr>
<th></th>
<th>CTX (nM)</th>
<th>PICP (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>+ IL-4</td>
</tr>
<tr>
<td>RA1</td>
<td>89.9 ± 54.2</td>
<td>17.5 ± 7.8</td>
</tr>
<tr>
<td>RA2</td>
<td>80.0 ± 7.9</td>
<td>1.0 ± 0.5</td>
</tr>
<tr>
<td>RA3</td>
<td>40.6 ± 14.5</td>
<td>5.3 ± 4.2</td>
</tr>
<tr>
<td>RA4</td>
<td>99.4 ± 7.3</td>
<td>44.3 ± 5.8</td>
</tr>
<tr>
<td>RA5</td>
<td>88.7 ± 5.4</td>
<td>63.0 ± 3.1</td>
</tr>
<tr>
<td>Mean of percent variation</td>
<td>-70 ± 28&lt;sup&gt;d&lt;/sup&gt;</td>
<td>932.7 ± 64</td>
</tr>
<tr>
<td>OA1</td>
<td>157.0 ± 8.5</td>
<td>19.2 ± 8.5</td>
</tr>
<tr>
<td>OA2</td>
<td>25.9 ± 15.3</td>
<td>20.2 ± 7.3</td>
</tr>
<tr>
<td>OA3</td>
<td>9.9 ± 1.6</td>
<td>3.7 ± 1.6</td>
</tr>
<tr>
<td>OA4</td>
<td>2.1 ± 1.1</td>
<td>1.9 ± 0.8</td>
</tr>
<tr>
<td>Mean of percent variation</td>
<td>-65 ± 31&lt;sup&gt;d&lt;/sup&gt;</td>
<td>300.1 ± 6.5</td>
</tr>
</tbody>
</table>

<sup>a</sup> RA and OA bone samples from five and four patients, respectively, were incubated for 7 days in the presence of IL-4 (50 ng/mL). <sup>b</sup> Levels of CTX and PICP in supernatants were measured by ELISA. Results are expressed as mean ± SD of culture triplicates with percent variations from baseline. <sup>c</sup> Column represents percent induction. <sup>d</sup> <i>P</i> < 0.05; differences between IL-4–treated and control group were compared with the paired Wilcoxon test.


